Altimmune, Inc. (NASDAQ:ALT) Short Interest Down 5.2% in January

Altimmune, Inc. (NASDAQ:ALT) was the recipient of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 23,320,000 shares, a decline of 5.2% from the January 15th total of 24,590,000 shares. Based on an average trading volume of 3,190,000 shares, the days-to-cover ratio is currently 7.3 days.

Wall Street Analysts Forecast Growth

ALT has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research note on Wednesday, February 5th. UBS Group assumed coverage on Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target for the company. Finally, Stifel Nicolaus began coverage on Altimmune in a research note on Wednesday, January 8th. They issued a “buy” rating and a $18.00 target price for the company. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $20.83.

Altimmune Trading Up 2.2 %

Shares of ALT opened at $6.37 on Tuesday. Altimmune has a 12-month low of $5.28 and a 12-month high of $14.84. The business’s 50 day moving average is $7.24 and its 200 day moving average is $7.18. The company has a market capitalization of $453.03 million, a PE ratio of -4.11 and a beta of 0.19.

Hedge Funds Weigh In On Altimmune

A number of institutional investors have recently modified their holdings of ALT. Larson Financial Group LLC acquired a new position in Altimmune during the 3rd quarter valued at about $31,000. SBI Securities Co. Ltd. purchased a new stake in Altimmune in the 4th quarter worth approximately $45,000. Virtus ETF Advisers LLC purchased a new stake in Altimmune during the fourth quarter worth $60,000. Cullen Frost Bankers Inc. acquired a new stake in Altimmune in the fourth quarter valued at approximately $72,000. Finally, 180 Wealth Advisors LLC purchased a new stake in Altimmune in the 4th quarter worth $78,000. 78.05% of the stock is owned by hedge funds and other institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.